# OnCo record genome-wide-loss-of-heterozygosity (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/genome-wide-loss-of-heterozygosity/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "genome-wide-loss-of-heterozygosity" ;
  schema:name "Genome-wide loss of heterozygosity (gLOH)"@en ;
  schema:alternateName "gLOH"@en, "genomic LOH"@en, "LOH score"@en, "genome-wide LOH"@en, "LOH-high"@en, "genomic scar score"@en ;
  schema:description "A score for how much of a tumour's genome has lost one of its two parental copies. A high score is a scar left behind by a broken DNA repair system, and is used as a rough sign that a PARP inhibitor might work. It is a measure of damage already done, not of the fault that caused it."@en ;
  schema:url <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Loss_of_heterozygosity> ;
  schema:citation <https://doi.org/10.1200/po.18.00283>, <https://doi.org/10.1200/po.19.00345>, <https://doi.org/10.1158/1078-0432.ccr-21-2096>, <https://doi.org/10.1016/s1470-2045(16)30559-9>, <https://doi.org/10.1200/jco.20.01035> ;
  onco:tag "gu", "prostate-glossary" ;
  onco:related <https://onco.cc/terms/hrd/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/terms/chromoplexy/>, <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/>, <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/cdk12/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:pathways <https://onco.cc/pathways/homologous-recombination-repair/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/>, <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/> .